Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Pravastatin × Gastrointestinal × Clear all
NCT03219372 2021-01-22

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Cedars-Sinai Medical Center

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01075555 2020-03-30

Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis

Federation Francophone de Cancerologie Digestive

Phase 3 Completed
323 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01357486 2017-05-01

PRODIGE 21

University Hospital, Bordeaux

Phase 2 Completed
160 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡